
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


RAPT Therapeutics Inc (RAPT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RAPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $22.33
1 Year Target Price $22.33
1 | Strong Buy |
1 | Buy |
4 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -92.03% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 186.05M USD | Price to earnings Ratio - | 1Y Target Price 22.33 |
Price to earnings Ratio - | 1Y Target Price 22.33 | ||
Volume (30-day avg) 7 | Beta 0.01 | 52 Weeks Range 5.66 - 26.56 | Updated Date 08/15/2025 |
52 Weeks Range 5.66 - 26.56 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.8 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.09 | Actual -0.65 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.24% | Return on Equity (TTM) -77.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20267182 | Price to Sales(TTM) 411.22 |
Enterprise Value 20267182 | Price to Sales(TTM) 411.22 | ||
Enterprise Value to Revenue 677.37 | Enterprise Value to EBITDA -10.73 | Shares Outstanding 16537800 | Shares Floating 6192742 |
Shares Outstanding 16537800 | Shares Floating 6192742 | ||
Percent Insiders 0.42 | Percent Institutions 95.5 |
Upturn AI SWOT
RAPT Therapeutics Inc

Company Overview
History and Background
RAPT Therapeutics, Inc. was founded in 2015. It is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for inflammatory diseases. They went public in 2020.
Core Business Areas
- Drug Development: Focuses on discovering and developing oral small molecule therapies for inflammatory diseases, specifically targeting chemokine receptors such as CCR4 and other novel targets.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various inflammatory conditions.
Leadership and Structure
RAPT Therapeutics is led by Brian Wong, M.D., Ph.D., the President and CEO. The company has a board of directors overseeing its strategic direction and a management team responsible for day-to-day operations.
Top Products and Market Share
Key Offerings
- FLX475: A CCR4 antagonist being developed for atopic dermatitis and other inflammatory conditions. Currently in clinical trials. There is no market share data available as the product is not yet approved. Competitors include companies developing treatments for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.
- RPT193: An oral small molecule CCR4 antagonist in clinical development for atopic dermatitis and asthma. Currently in clinical trials. There is no market share data available as the product is not yet approved. Competitors include companies developing treatments for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with numerous companies developing therapies for inflammatory diseases. The demand for novel and effective treatments for these conditions is substantial.
Positioning
RAPT Therapeutics is positioned as an innovative company focused on developing oral small molecule therapies for inflammatory diseases, differentiating itself through its target specificity and oral delivery approach.
Total Addressable Market (TAM)
The total addressable market for inflammatory disease therapeutics is estimated to be in the tens of billions of dollars annually. RAPT Therapeutics is positioned to capture a portion of this market with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug development platform
- Strong intellectual property portfolio
- Experienced management team
- Targeting large unmet medical needs
Weaknesses
- Clinical trial risk
- Limited revenue generation
- Dependence on external funding
- Small company size
Opportunities
- Successful clinical trial outcomes
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new indications
- Acquisition by a larger company
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Patent challenges
Competitors and Market Share
Key Competitors
- SNY
- REGN
- ABBV
- PFE
Competitive Landscape
RAPT Therapeutics faces intense competition from larger, well-established pharmaceutical companies. Its competitive advantage lies in its novel drug development platform and oral small molecule approach.
Growth Trajectory and Initiatives
Historical Growth: RAPT Therapeutics has experienced growth in its research and development activities, as evidenced by the advancement of its drug candidates through clinical trials.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include the advancement of FLX475 and RPT193 through clinical trials, as well as the identification and development of new drug candidates.
Summary
RAPT Therapeutics is a clinical-stage biopharmaceutical company with potential in developing oral therapies for inflammatory diseases. Its success hinges on positive clinical trial results and strategic partnerships. The company faces risks associated with drug development, competition, and funding. Their lack of current products on the market is impacting their market share. They are developing novel drugs and that could position them as a stronger company in the future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Third-party market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RAPT Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-10-31 | CEO, President & Director Dr. Brian Russell Wong M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.rapt.com |
Full time employees 61 | Website https://www.rapt.com |
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.